research use only
Cat.No.S6502
| Related Targets | ERK Raf JNK MEK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase |
|---|---|
| Other p38 MAPK Inhibitors | SB202190 SB203580 (Adezmapimod) PH-797804 Doramapimod (BIRB 796) Ralimetinib (LY2228820) dimesylate VX-702 Losmapimod SB239063 Neflamapimod (VX-745) BMS-582949 |
|
In vitro |
DMSO
: 80 mg/mL
(201.07 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 397.86 | Formula | C20H20ClN5O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 271576-80-8 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CN(CCC1C2=C(C(=NN2)C3=CC=C(C=C3)Cl)C4=NC=NC=C4)C(=O)CO | ||
| Targets/IC50/Ki |
p38α
(Cell-free assay) 0.016 μM
p38β
(Cell-free assay) 0.677 μM
|
|---|---|
| In vitro |
SD0006 is selective for p38α kinase over 50 other kinases screened (including p38γ and p38δ with modest selectivity over p38β). It suppresses Inflammatory mediator release in cellular studies. SD0006 suppresses expression of multiple proinflammatory proteins at both the transcriptional and translational levels. In RASFs, SD0006 has no direct inhibitory activity against COX-1 or COX-2, yet it could completely inhibit in a dose-dependent manner the release of IL-1β-stimulated PGE2 with an IC50 of 96.2 nmol/l. |
| In vivo |
In vivo, SD0006 is effective in animal models of chronic inflammation and disease. It is effective in the rat streptococcal-cell-wall-induced arthritis model, with dramatic protective effects on paw joint integrity and bone density. SD0006 also demonstrates good oral anti-inflammatory efficacy with excellent cross-species correlation between the rat, cynomolgus monkey, and human. It alleviates swelling and pain in a rodent acute inflammation model. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.